Press release

Henry Schein Medical and MindChild Medical Announce an Exclusive Distribution and Supply Agreement for the MERIDIAN M110 Fetal Monitoring System

Sponsored by Businesswire

Henry Schein Medical, the U.S. Medical business of Henry Schein, Inc.,
and MindChild Medical, Inc. today announced the signing of an exclusive
distribution and supply agreement for the MERIDIAN™ M110 Fetal
Monitoring System. The MERIDIAN M110, currently available to Henry
Schein customers, is an intrapartum fetal monitor that externally
measures and displays fetal heart rate (FHR), maternal heart rate (MHR),
and uterine contractions (UA). As part of the agreement, Henry Schein
Medical will distribute the monitor to its obstetricians and pediatric
cardiologist customers in the U.S.

This press release features multimedia. View the full release here:

Henry Schein Medical signs an exclusive distribution and supply agreement for MindChild's MERIDIAN™  ...

Henry Schein Medical signs an exclusive distribution and supply agreement for MindChild’s MERIDIAN™ M110 Fetal Monitoring System. (Photo: Business Wire)

William Edelman, Chief Executive Officer, MindChild stated, “We are
thrilled to enter into this agreement with Henry Schein Medical, one of
the preeminent distributors of medical devices and leading solutions
companies for health care professionals in the U.S. We look forward to
supporting Henry Schein, as they bring the MERIDIAN Fetal Monitoring
System to the labor and delivery market.”

In a labor and delivery (L&D) setting, the MERIDIAN M110 derives these
vital signs from maternal and fetal electrocardiogram (ECG) and uterine
contraction signals captured via electrodes on the surface of a mother’s
abdomen. These vital signs are then displayed on existing primary fetal
monitors. The MERIDIAN M110 is indicated for use on women who are at ≥37
weeks into their pregnancy, in labor, and is intended for use only by
health care professionals in a clinical setting, such as an L&D
Department or birthing center.

“This is a great milestone for MindChild and Henry Schein and, more
importantly, will result in excellent care to millions of women and
newborns,” said Brad Connett, President, U.S. Medical Group for Henry
Schein. “MindChild’s unique ability to monitor both fetal and maternal
heart rates at the same time fits well with Henry Schein’s commitment to
offering the finest solutions customers can rely on to deliver critical
patient care.”

Adam Wolfberg, M.D., Chief Medical Officer, MindChild added, “The
ability to monitor accurate fetal heart rate by extracting ECG
information while simultaneously monitoring maternal heart rate, as well
as uterine contraction, is a tremendous achievement. As the MERIDIAN
M110 enters the labor and delivery market, new diagnostic capabilities
will undoubtedly emerge, providing insight into fetal management not
currently available.”

Dr. Wolfberg continued, “In the coming months and years, MindChild will
build on this technology to improve the safety of obstetrics, and
provide a new diagnostic device to obstetricians and pediatric

England & Company served as financial and strategic advisor to MindChild
relating to the exclusive distribution and supply agreement.

On January 17, 2017, MindChild Medical, Inc. announced the clearance of
its 510(k) Pre‐Marketing Notification Application with the U.S. Food and
Drug Administration for the MERIDIAN™ M110 Line of Non‐Invasive Fetal
Heart Rate Monitors.

For more information, or to order MindChild products, please contact a
Henry Schein sales consultant at (800) 772-4346.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care
professionals powered by a network of people and technology. With more
than 18,000 Team Schein
 worldwide, the Company’s network of trusted advisors
provides more than 1 million customers globally with more than 300
valued solutions that improve operational success and clinical outcomes.
Our Business, Clinical, Technology, and Supply Chain solutions help
office-based dental and medical practitioners
work more efficiently so they can provide quality care more effectively.
These solutions also support dental
and institutional health care clinics
, as well as other alternate
care sites.

Henry Schein operates through a centralized and automated distribution
network, with a selection of more than 120,000 branded products and
Henry Schein private-brand products in stock, as well as more than
180,000 additional products available as special-order items.

A FORTUNE 500 Company and a member of the S&P 500® and the Nasdaq 100®
indexes, Henry Schein is headquartered in Melville, N.Y., and has
operations or affiliates in 31 countries. The Company’s sales from
continuing operations reached $9.4 billion in 2018, and have grown at a
compound annual rate of approximately 13 percent since Henry Schein
became a public company in 1995.

For more information, visit Henry Schein at,,
and @HenrySchein
on Twitter

About MindChild Medical, Inc.

MindChild Medical, Inc., is a privately funded medical device company
founded in 2008. MindChild’s principal technology platform, the MERIDIAN
M110 non-invasive fetal electrocardiograph (fECG), maternal heart rate
(MHR) and uterine contractions (UA) monitor, is designed to report fetal
heart rate data equivalent to the gold standard fetal scalp electrode,
report uterine contraction data equivalent to the gold standard
intrauterine pressure cathode, as well as novel ECG metrics intended to
provide obstetricians a deeper understanding of fetal/maternal health
and management.

MindChild was co-founded by Adam Wolfberg, MD, Assistant Professor,
Tufts Medical Center, Gari Clifford, PhD, previously Principal Research
Scientist at Harvard-MIT Division of Health and Science Technology
(currently Interim Chair, Associate Professor, Biomedical Informatics
(Emory University)), James Robertson, President and CEO, and Jay Ward,
Executive Vice President, both of E-TROLZ, Inc. MindChild has
exclusively licensed intellectual property from MIT, Tufts Medical
Center and E-TROLZ, Inc., a Massachusetts technology company that
develops and commercializes breakthrough physiologic monitoring
platforms for a wide variety of applications. For more information,
please visit

About England & Company

With offices in New York, Houston and Washington, DC, England & Company
is an independent investment banking and advisory firm dedicated to the
middle market. Since the founding of England in 2003, the firm has
provided honest and effective advice on mergers and acquisitions,
private capital raising, financial restructuring, fairness opinions and
valuations, and strategic advisory to the executive teams, boards of
directors, and financial sponsors of public and private companies.

About the MERIDIAN M110 Non-Invasive Fetal Heart Rate Monitor

MERIDIAN M110 is a maternal-fetal monitor that non-invasively measures
and displays fetal heart rate (FHR), maternal heart rate (MHR) and
uterine contractions (UA). MERIDIAN acquires and displays the FHR and
MHR from abdominal surface electrodes that detect the fetal ECG signal
(fECG), maternal ECG and uterine muscle contraction signals. MERIDIAN
M110 is designed for women who are at term (≥ 37 completed weeks), in
labor, with singleton pregnancies. MERIDIAN M110 is intended for use
only by healthcare professionals in a clinical setting.

About the Fetal Heart Monitoring Market

Over 85%1 of the 4,000,0002 live births in the US
during 2011 required fetal monitoring during labor and delivery. Current
non-invasive Doppler, employing ultrasound to detect FHR is subject to
loss of fetal heart rate due to maternal/fetal movement3.
Fetal Scalp Electrodes (FSE) that connect directly to the fetus during
the later stages of labor and delivery are invasive devices associated
with increased risk of maternal/fetal infection4. There are
an estimated 28,000 fetal monitors spread over 3,400 hospitals in the US5,
representing an investment of over $700,000,0006. MERIDIAN
has been developed to provide uninterruptible fECG data while addressing
the deficiencies in both Doppler and FSE via innovative non-invasive
monitoring technology.


1 “ACOG Refines Fetal Heart Rate Monitoring
Guidelines”, 6/22/2009 The American College of Obstetricians and
Gynecologists Press Release


3 Journal of Midwifery. Vol 18, No, 7: 424-428. July 2010
4 American Family Physician, 1992 Feb;45(2):579-82


6 Company estimates.